Related Experiment Video

Updated: Dec 18, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.8K

COVID-19 in a Patient with Liver Cirrhosis

Edita Kreivenaite1, Rolandas Gedgaudas2, Irena Valantiene3

  • 1Lithuanian University of Health Sciences, Medical Academy, Department of Gastroenterology, Kaunas, Lithuania. . edita.kreivenaite@gmail.com.

Journal of Gastrointestinal and Liver Diseases : JGLD
|June 13, 2020
PubMed

Insights

This case report details a patient with liver cirrhosis and COVID-19, showing mild liver enzyme changes and symptom resolution. Early COVID-19 testing is recommended for cirrhotic patients in endemic areas.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Internal Medicine

Background:

  • The global outbreak of coronavirus disease 2019 (COVID-19) presents a significant public health challenge.
  • Abnormal liver function tests are frequently observed in COVID-19 patients, but their clinical significance remains unclear.
  • Liver cirrhosis is a chronic condition that may predispose patients to severe outcomes from viral infections.

Observation:

  • This report describes the first case of a patient with co-existing liver cirrhosis and COVID-19 at our center.
  • The patient experienced COVID-19 symptoms, including fever, which resolved within six days.
  • Liver function tests, including enzymes, bilirubin, and INR, showed only minor fluctuations without apparent clinical impact.

Findings:

  • The patient's COVID-19 infection did not lead to significant decompensation of underlying liver cirrhosis.
  • Mild, transient changes in liver enzymes and coagulation parameters were noted.
  • The case highlights the potential for recovery from COVID-19 even in patients with advanced liver disease.

Implications:

  • Routine testing for severe acute respiratory syndrome coronavirus (SARS-CoV-2) should be considered for all patients with liver cirrhosis presenting for care in COVID-19 prevalent areas.
  • Early identification of COVID-19 in cirrhotic patients may allow for timely management and potentially prevent severe complications.
  • Further research is warranted to understand the specific interactions between COVID-19 and liver cirrhosis.

More Related Videos

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

561
Laparoscopic S7 Hepatectomy with Positive Fluorescence Staining07:43

Laparoscopic S7 Hepatectomy with Positive Fluorescence Staining

Published on: May 9, 2025

525

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
148
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
287
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
116
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
4.7K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
122